Skip to main content
. 2001 Jul 1;108(1):73–81. doi: 10.1172/JCI12466

Figure 8.

Figure 8

(a) Effect of SP600125 on adjuvant arthritis in rats. Rats were immunized with complete Freund’s adjuvant on day 0 and treated with vehicle or 30 mg/kg/d of SP600125 subcutaneously beginning on day 8. Significantly less paw swelling was observed in the treated animals. (b) Effect of SP600125 on radiographic damage in adjuvant arthritis. Representative examples of ankle radiographs demonstrate markedly less destruction in the rats treated with SP600125 (top) compared with vehicle (bottom). (c) Effect of SP600125 on synovial collagenase gene expression. Northern blot analysis was performed on joint extracts of vehicle and SP600125-treated rats. Each lane contains the extract of an ankle joint from a control or treated rat (n = 4 for each). Note the lower levels of MMP13 in the SP600125-treated animals (G3PDH-normalized MMP13 mRNA levels for SP600125 = 0.23 ± 0.086 and vehicle = 0.822 ± 0.131; P < 0.01). (d) Effect of SP600125 on synovial AP-1 activation. EMSA analysis was performed on joint extracts of vehicle and SP600125-treated rats with adjuvant arthritis. Positive control is shown on the far left lane of the gel. Note lower levels of AP-1 binding in the SP600125-treated rats (SP600125 = 2.89 ± 0.43 and vehicle = 12.6 ± 2.5, P < 0.01; data presented as arbitrary density units).